Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Safety of HMG-CoA reductase inhibitors: Focus on atorvastatin
Autore:
Bernini, F; Poli, A; Paoletti, R;
Indirizzi:
Univ Parma, Inst Pharmacol & Pharmacognosy, I-43100 Parma, Italy Univ Parma Parma Italy I-43100 col & Pharmacognosy, I-43100 Parma, Italy Univ Milan, Dept Pharmacol Sci, I-20129 Milan, Italy Univ Milan Milan Italy I-20129 Dept Pharmacol Sci, I-20129 Milan, Italy
Titolo Testata:
CARDIOVASCULAR DRUGS AND THERAPY
fascicolo: 3, volume: 15, anno: 2001,
pagine: 211 - 218
SICI:
0920-3206(200105)15:3<211:SOHRIF>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
CORONARY-HEART-DISEASE; SCANDINAVIAN SIMVASTATIN SURVIVAL; RENAL-TRANSPLANT RECIPIENTS; AVERAGE CHOLESTEROL LEVELS; PLASMA-FIBRINOGEN LEVEL; LONG-TERM SAFETY; HYPERCHOLESTEROLEMIC PATIENTS; CARDIAC TRANSPLANTATION; RECEIVING LOVASTATIN; DIABETIC-PATIENTS;
Keywords:
HMG-CoA reductase inhibitors; atorvastatin; hypercholesterolemia; adverse effects; drug interactions;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
93
Recensione:
Indirizzi per estratti:
Indirizzo: Bernini, F Univ Parma, Inst Pharmacol & Pharmacognosy, Viale Sci, I-43100 Parma, Italy Univ Parma Viale Sci Parma Italy I-43100 I-43100 Parma, Italy
Citazione:
F. Bernini et al., "Safety of HMG-CoA reductase inhibitors: Focus on atorvastatin", CARDIO DRUG, 15(3), 2001, pp. 211-218

Abstract

Statins effectively lower LDL-cholesterol and some members of this class have been shown to reduce the risk of major cardiovascular events and total mortality in patients with or at risk for coronary heart disease. Statins are in general well tolerated. Withdrawal rates related to adverse events are low (less than or equal to3%). The most common adverse events are mild gastrointestinal symptoms. Elevated serum transaminase levels occur infrequently (less than or equal to1.5%). These are generally asymptomatic, reversible and rarely require drug withdrawal. Statins do not cause adverse endocrine effects, do not alter glycemic control in diabetic patients, and do not increase cancer risk. Dose-related myopathy and/or rhabdomyolysis also occurs very rarely, although the risk is increased by concomitant administration of cyclosporine, niacin, fibrates, or by CYP3A4 isoenzyme inhibitors (e.g. erythromycin, systemic azole antifungal agents etc.) with statins metabolized by this isoenzyme. The pharmacokinetics of the individual statin should be considered in patients receiving polypharmacological treatments, to minimize the risk of unfavorable drug interactions. Atorvastatin is well tolerated in long-term treatment of dyslipidemia and is characterized by a safety profile similar to the other available statins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 06/04/20 alle ore 01:34:27